Top Biotechnology Startups in 2026

Medtronic provides healthcare technology solutions for complex and challenging conditions. They deliver treatments and therapies for the lungs, brain, dental, diabetes, ENT, heart, gastrointestinal, orthopedic, urinary, and women's health. The company's technologies and therapies treat 70 different medical conditions and include patient monitoring systems, robotic surgery, insulin pumps, cardiac devices, and more. Medtronic delivers innovative technologies that change people's lives through to its extensive knowledge, insatiable curiosity, and desire to assist everyone in need.

Our product line extends to over 24,000 products, 95% of them manufactured in-house. While maintaining our core strengths in cytokines and immunoassays, we also develop antibodies, cell selection and multicolor flow cytometry kits, multiplex assays, biologically active compounds, and stem cell products and kits, as well as maintaining a clinical hematology laboratory with the most diversified instruments capabilities in the industry. The company brings its diverse expertise and the combined strengths of its product offerings to the research and diagnostic communities, providing the resources needed to advance life sciences research and support clinical breakthroughs.

At Anivive, we are using software and cutting-edge technologies to change the landscape of pet health. We are developing a diverse suite of technologies to address the unmet medical needs of our pets. Not only do we work to bring new treatments to our pets but we also believe that improving pet health is much more than just developing novel treatments and our software tools help change the way we interact and care for our pets. We accomplish this by combining artificial intelligence software, biotech, and thoughtful design to change the way new therapies are discovered, developed, and used by people worldwide. Our mission is to use technology to make pet medicine more affordable. Our goal is to change the way people interact with and understand pet health.

We have extensive expertise in method development, validation, and transfer, mass spectrometric and chromatographic (LC-MS) bioanalysis, pharmacokinetics (PK) sample analysis, toxicokinetic safety testing, as well as other custom assay services. Our assay services include ELISA based assay, cell-based assay, biomarker testing, immunogenicity testing, biochemical assay, and Mechanism of Action (MoA) studies.

The protocol enables new economic incentive models for distributed research and development. We leverage open science and blockchain technology to create a fair and accountable market-based platform for discovery and funding of pharmaceutical intellectual property. The ecosystem aims to align all stakeholders - academia, pharmaceutical corporations, consumers, biotech companies, investors, regulators, and lawyers - to collaborate in an open, incentive-based market.

Scientific progress in medicine is accelerating, but getting breakthroughs to patients remains slow and unreliable. Bringing a new drug to market takes 10 to 15 years and costs $2.6 billion on average. Even after FDA approval, too many eligible patients never receive treatment – caught in a system that wasn't built for the complexity of modern medicine. Most promising drugs never make it to market, and those that do reach only a fraction of the patients who could benefit. Forus is embedded into physician workflows, automating all steps between a clinical decision and a patient starting treatment — insurance authorization, financial assistance, and fulfillment routing — across every drug, payer, and pharmacy in the country, free for doctors and patients. Because we play an unprecedented role in moving prescriptions through the system, we provide life sciences companies unmatched insight into how medicines perform — enabling them to design better research, launch new drugs more effectively, and invest in harder-to-treat conditions. Our number one priority is scaling to market demand. We are looking for individuals who are high horsepower, high throughput, and hyper resourceful to help us unlock capacity and drive growth. We move fast and need to move faster.

Machine learning-enabled platform for drug discovery and development.

Novel therapeutics to treat diseases of aging.

Munch is the developer of the Brainwave Interference Protocol, a cryptocurrency designed to regulate a planetarily-correct evolution of the constructive and destructive communication cycles that build up and break down the planet and its life by incentivizing phasic alignment between a life's brainwaves and the ionospheric or "Schumann" resonance.